Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + IBI310 + lenvatinib
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of sintilimab, an anti-PD-1 monoclonal antibody; IBI310, an anti-CTLA-4 monoclonal antibody; and lenvatinib, a multi-kinase inhibitor. It is currently being evaluated in a Phase 2 clinical trial (NCT05534282) sponsored by Peking University for the treatment of non-metastatic gastric or colon cancers that are mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). The therapeutic strategy aims for organ preservation by utilizing an initial phase of PD-1/PD-L1 antibody monotherapy followed by an intensive combination of the three agents to achieve a complete clinical response, thereby potentially avoiding the need for radical surgery. Sintilimab and IBI310 are developed by Innovent Biologics, while lenvatinib is developed by Eisai.
- Brand names
- TyvytLenvima
- Other names
- sintilimab + IBI310 + lenvatinib combination therapy
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)FGFR3 (Fibroblast growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on sintilimab + IBI310 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + IBI310 + lenvatinib.